OVX033 Pan-Sarbecovirus T-cell based vaccine

WHO Global Consultation - Vaccine developers panel
How can pan–sarbecovirus vaccines be rapidly developed and evaluated?
28 January 2022
This Presentation (the Memorandum) is intended solely for informational use by prospective corporate partners of OSIVAX. The information contained herein has been prepared to assist interested parties in making their own evaluation of the Transaction opportunity and may not contain all of the information that a prospective counterparty may need or desire. In all cases, interested parties should conduct their own investigation and analysis of the Transaction opportunity and of the data set forth in this Memorandum.

Neither OSIVAX nor any other party makes any representation or warranty (express or implied) as to the accuracy or completeness of the information, including projections, contained herein, nor shall OSIVAX or any other party have any liability for any actual or alleged representations or misrepresentations (express or implied) contained in, or for any omissions or alleged omissions from, this Memorandum. Only those particular representations and warranties which may be made to a party in a definitive agreement, when, as and if such an agreement shall be executed, and subject to all restrictions and limitations contained therein, shall have any legal effect. The Memorandum shall remain the property of OSIVAX. The Memorandum shall not be copied, reproduced or distributed to third parties at any time without the prior written consent of OSIVAX; it has been prepared for information purposes only with the express understanding that the recipient will use it only for the purpose set forth above.
Leading experts insist on the critical role of T-cell against N to develop pan-sarbecovirus vaccines

**WHO consultation on COVID-19 vaccines research**: How can vaccine research further contribute to achieve the control of the pandemic everywhere? – 6 Dec 2021 - Stanley Plotkin and Rafi Ahmed

**Importance of including nucleocapsid protein in SARS-CoV-2 vaccines for inducing an optimal CD8 T cell response**
A Double-Punch Approach is Necessary for Broad-Spectrum Protection against Sarbecoviruses

Osivax’s ambition: Provide a clinically validated, safe and cost-effective T-cell component
Why can Osivax succeed in developing a T-cell component against the Nucleocapsid?

**Osivax’s Technology specifically designed to trigger T-cell responses**

Osivax recombinant proteins self-assemble into highly immunogenic nanoparticles, composed of:

- **Full-length** Nucleocapsid antigen
- Together with 3 critical immunologic features
  1. **Repetitive patterns** (self-assembling sequence)
  2. **Cell penetrating system** (polyarginine tail)
  3. **T-cell activation sequence** (CD40 receptor)

**Osivax’s Technology de-risked in clinical Phase 2 in Influenza (OVX836 vaccine)**

Insights from OVX836, OSIVAX’ influenza vaccine:

- Excellent **safety** profile in >500 subjects
- **T-cell** responses generated in human
- **Cost-effective** manufacturing process
- Signal of **efficacy** synergistic with conventional vaccines in both preclinical and human
We’re looking for collaborations with teams developing Spike Ab-based vaccines

Please do not hesitate to contact us:
Delphine GUYON-GELLIN – dguyongellin@osivax.com
Head of Coronavirus Program

Acknowledgements

- Florence NICOLAS
- Marjorie HALLER
- Marion CHEVANDIER
- Julien BOULEY
- Judith DEL CAMPO
- Charlotte PRIMARD
- Alexandre LE VERT
- Elodie MONCHATRE- LEROY
- Franck BOUE
- Alexandre SERVAT
- Marine WASNIEWSKI
- Evelyne PICARD-MEYER
- Laboratory for Rabies and Wildlife of Nancy (LRFSN)

This project is supported by the French State, through the Banque Publique d'Investissement France’s programme: Programme d'investissements d'avenir
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 961112.